The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Upcoming agents for the treatment of SCD
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, highlights some upcoming agents for the treatment of sickle cell disease (SCD), drawing focus on PKR activators and gene therapies, as well as agents that may help improve vascular health. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
